Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
HQ Bio is a London-based synthetic biology company specializing in the production of high-purity, large-scale synthetic DNA. The company's core technology, the oDNA (optimized DNA) platform, provides an alternative to traditional plasmid DNA, which often faces challenges related to manufacturing complexity and scalability. HQ Bio's approach enables the rapid and cost-effective production of DNA for use in advanced medicinal products, including gene therapies and mRNA vaccines. By addressing the DNA bottleneck, the company seeks to streamline the development and commercialization of next-generation therapeutics. The platform is designed to be modular and scalable, supporting the industry's shift toward more complex and personalized genetic medicines.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on HQBIO.